AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23009373 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 20122351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint-flavoured, alcohol-based mouthwash
Number of subjects: 15
Study 20122351 — intervention group
Group type: COMPARATOR
Intervention: Plain water (placebo)
Number of subjects: 15
Study 18801404 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (highest dose 32 mg/day)
Number of subjects: 218
Study 18801404 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (highest dose 200 mg/day)
Number of subjects: 218
Study 15739214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sphincterotomy (LAS)
Number of subjects: 132
Study 15739214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sphincterotomy (LAS) and tailored sphincterotomy (TS)
Number of subjects: 132
Study 15739214 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 132
Study 15739214 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (LAS, TS, and nifedipine)
Number of subjects: 132
Study 14716878 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-HAb18F(ab')2 injected into the target hepatic artery at doses of 0.5, 0.75, 1.0 mCi/kg
Number of subjects: 24
Study 14716878 — intervention group
Group type: COMPARATOR
Intervention: Lugol's Liquid to block the thyroid gland
Number of subjects: 24
Study 10362732 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mg. kg-1. h-1)
Number of subjects: 21
Study 10362732 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (75 or 180 micrograms . kg-1. h-1)
Number of subjects: 21
Study 10362732 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 21
Study 8895035 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute (50% NaCl, 40% KCL, 10% Mg2+)
Number of subjects: 40
Study 8895035 — intervention group
Group type: COMPARATOR
Intervention: Whole salt intake
Number of subjects: 40
Study 2034831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 7
Study 2034831 — intervention group
Group type: EXPERIMENTAL
Intervention: FET
Number of subjects: 7
Study 2034831 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study 6661351 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 14
Study 6661351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31870338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 995
Study 31870338 — intervention group
Group type: COMPARATOR
Intervention: Mustard seed oil (MO)
Number of subjects: 995
Study 27411361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with AV delay optimization
Number of subjects: 87
Study 27411361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with reduced LV activation time
Number of subjects: 87
Study 27411361 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ventricular fusion
Number of subjects: 87
Study 27411361 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening AV delay in patients with ventricular fusion
Number of subjects: 87
Study 26070467 — intervention group
Group type: COMPARATOR
Intervention: Angio-Seal(®)
Number of subjects: 319
Study 26070467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exo-Seal(®)
Number of subjects: 319
Study 24255104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/day for 48 weeks
Number of subjects: 227
Study 24255104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 22971188 — intervention group
Group type: EXPERIMENTAL
Intervention: High UVA-protection sunscreen applied at 2 mg/cm²
Number of subjects: 15
Study 22971188 — intervention group
Group type: COMPARATOR
Intervention: Low UVA-protection sunscreen applied at 2 mg/cm²
Number of subjects: 15
Study 22971188 — intervention group
Group type: EXPERIMENTAL
Intervention: High UVA-protection sunscreen applied at 1 mg/cm²
Number of subjects: 15
Study 22971188 — intervention group
Group type: COMPARATOR
Intervention: Low UVA-protection sunscreen applied at 1 mg/cm²
Number of subjects: 15
Study 19200365 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days
Number of subjects: 0
Study 19200365 — intervention group
Group type: COMPARATOR
Intervention: RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later
Number of subjects: 0
Study 19200365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU)
Number of subjects: 0
Study 17095923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg(‐1) body mass in 1 L of fluid)
Number of subjects: 7
Study 17095923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 7
Study 15266180 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐depreotide (NeoTect)
Number of subjects: 9
Study 11354392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin MR 500 mg once daily
Number of subjects: 244
Study 11354392 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin IR 250 mg twice daily
Number of subjects: 244
Study 9272404 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 18
Study 9272404 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen
Number of subjects: 18
Study 9272404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7877334 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture (EA) at Chen Time (7 a.m. to 9 a.m.)
Number of subjects: 0
Study 7877334 — intervention group
Group type: COMPARATOR
Intervention: Electric acupuncture (EA) at Xu Time (7 p.m. to 9 p.m.)
Number of subjects: 0
Study 3155334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentine adhesives and composites used in combination
Number of subjects: 152
Study 31852207 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane + high-dose remifentanil (SH)
Number of subjects: 60
Study 31852207 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane + low-dose remifentanil (SL)
Number of subjects: 60
Study 31852207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + high-dose remifentanil (PH)
Number of subjects: 60
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-1 formula (12.3% incidence of haematoma enlargement at 24 hours)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-2 formula (7.5% incidence of haematoma enlargement at 24 hours)
Number of subjects: 324
Study 31076468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7.8% incidence of haematoma enlargement at 24 hours)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-1 formula (1.1% incidence of haematoma enlargement on day 10)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-2 formula (3.1% incidence of haematoma enlargement on day 10)
Number of subjects: 324
Study 31076468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.1% incidence of haematoma enlargement on day 10)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-1 formula (2.8% mortality rate)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-2 formula (0.9% mortality rate)
Number of subjects: 324
Study 31076468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.8% mortality rate)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-1 formula (6.0% poor prognosis incidence)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-2 formula (4.8% poor prognosis incidence)
Number of subjects: 324
Study 31076468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7.1% poor prognosis incidence)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-1 formula (12.1% treatment-emergent adverse events)
Number of subjects: 324
Study 31076468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5.8% treatment-emergent adverse events)
Number of subjects: 324
Study 31076468 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH-2 formula (2.8% treatment-emergent adverse events)
Number of subjects: 324
Study 28266765 — intervention group
Group type: EXPERIMENTAL
Intervention: OCV-C02 (0.3 mg/body)
Number of subjects: 24
Study 28266765 — intervention group
Group type: EXPERIMENTAL
Intervention: OCV-C02 (1 mg/body)
Number of subjects: 24
Study 28266765 — intervention group
Group type: EXPERIMENTAL
Intervention: OCV-C02 (3 mg/body)
Number of subjects: 24
Study 28266765 — intervention group
Group type: EXPERIMENTAL
Intervention: OCV-C02 (6 mg/body)
Number of subjects: 24
Study 28266765 — intervention group
Group type: EXPERIMENTAL
Intervention: OCV-C02 (0.3 to 6 mg/body)
Number of subjects: 24
Study 25719544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel face mask
Number of subjects: 56
Study 25719544 — intervention group
Group type: COMPARATOR
Intervention: Laerdal face mask
Number of subjects: 56
Study 24096971 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based obesity prevention program
Number of subjects: 405
Study 24096971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 405
Study 21518064 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt awakening at 03:00h (<3h sleep)
Number of subjects: 20
Study 21518064 — intervention group
Group type: COMPARATOR
Intervention: Control group slept until 07:30h
Number of subjects: 20
Study 18054354 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic tubal anastomosis
Number of subjects: 0
Study 18054354 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy tubal anastomosis
Number of subjects: 0
Study 16794386 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ilioinguinal neurectomy (group A)
Number of subjects: 100
Study 16794386 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal nerve preservation (group B)
Number of subjects: 100
Study 14678271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (4 g orally, total dose of 8 g)
Number of subjects: 10
Study 14678271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28) + Dextroamphetamine (20 mg on Days 22-28)
Number of subjects: 32
Study 11936571 — intervention group
Group type: COMPARATOR
Intervention: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28)
Number of subjects: 32
Study 11928147 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular implant (TMI)
Number of subjects: 88
Study 11928147 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implant
Number of subjects: 88
Study 11928147 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark system (BRA)
Number of subjects: 88
Study 11928147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Implant Performance scale (CIP)
Number of subjects: 88
Study 7774069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CSA) at doses <5 mg/kg/day
Number of subjects: 29
Study 2626336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg)
Number of subjects: 19
Study 2626336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 5077919 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reporting of adverse reactions to drugs
Number of subjects: 82
Study 31411968 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsies alone (n=283)
Number of subjects: 640
Study 31411968 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted biopsies (n=357)
Number of subjects: 640
Study 30696178 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Gbaud PSK Y-00 quantum stream cipher transmission system
Number of subjects: 0
Study 27712461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate treatment (n = 218 teeth)
Number of subjects: 62
Study 27712461 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (n = 216 teeth)
Number of subjects: 62
Study 25791540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (10 mg)
Number of subjects: 67
Study 25791540 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg) plus lorazepam (2 mg)
Number of subjects: 67
Study 23335971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions over 2 months, 5 days/week, 90 minutes each, 100% oxygen at 2 ATA
Number of subjects: 74
Study 23335971 — intervention group
Group type: COMPARATOR
Intervention: Control group (cross group) - no treatment for 2 months followed by 40 HBOT sessions
Number of subjects: 74
Study 21617163 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon plus EPC stent
Number of subjects: 120
Study 21617163 — intervention group
Group type: COMPARATOR
Intervention: EPC stent alone
Number of subjects: 120
Study 19905932 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium composite (BCC)
Number of subjects: 45
Study 19905932 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone spongiosa (ABS)
Number of subjects: 45
Study 19905932 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 45
Study 16940980 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (90 mg/m(2) three times weekly) concomitant to hyperfractionated accelerated radiotherapy (HART)
Number of subjects: 33
Study 16940980 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 and HART
Number of subjects: 33
Study 14752416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin raffimer
Number of subjects: 60
Study 14752416 — intervention group
Group type: COMPARATOR
Intervention: Control (10% pentastarch)
Number of subjects: 60
Study 11275541 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 68
Study 11275541 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 68
Study 9129484 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100
Number of subjects: 7
Study 9129484 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided doses of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100 and 0200
Number of subjects: 7
Study 7964948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dosage of 30 to 38 Gy in 2- to 3.6-Gy fractions
Number of subjects: 1617
Study 7964948 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (PCI)
Number of subjects: 1617
Study 7964948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 1617
Study 3581696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic drug treatment (T-group)
Number of subjects: 22
Study 3581696 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic drugs only (NT-group)
Number of subjects: 22
Study 30852882 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 90
Study 30852882 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 90
Study 29625014 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group waited, out-group did not wait
Number of subjects: 2
Study 29625014 — intervention group
Group type: COMPARATOR
Intervention: Control condition (assigned to a group with no information about delay behavior)
Number of subjects: 2
Study 26652606 — intervention group
Group type: EXPERIMENTAL
Intervention: Live More intervention (n=24)
Number of subjects: 288
Study 26652606 — intervention group
Group type: COMPARATOR
Intervention: Control receiving only country specific Ministry of Health literature (n=24)
Number of subjects: 288
Study 23238223 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy (mCIMT)
Number of subjects: 31
Study 23238223 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 31
Study 21409353 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan's balloon applied during peribulbar anesthesia
Number of subjects: 120
Study 21409353 — intervention group
Group type: COMPARATOR
Intervention: No ocular compression (control group)
Number of subjects: 120
Study 18672299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 17
Study 18672299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16611388 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg policosanol daily for 12 weeks
Number of subjects: 19
Study 16611388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14508426 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professional visit
Number of subjects: 90
Study 14508426 — intervention group
Group type: COMPARATOR
Intervention: Intervention group 1
Number of subjects: 90
Study 14508426 — intervention group
Group type: COMPARATOR
Intervention: Intervention group 2
Number of subjects: 90
Study 14508426 — intervention group
Group type: COMPARATOR
Intervention: Intervention group 3
Number of subjects: 90
Study 10753259 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A therapy
Number of subjects: 0
Study 10753259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8833493 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiogram (SA-ECG) analysis using fast-Fourier transformation
Number of subjects: 23
Study 8833493 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter processing of low frequency components
Number of subjects: 23
Study 8833493 — intervention group
Group type: EXPERIMENTAL
Intervention: Area ratios of 40-100 Hz/0-40 Hz
Number of subjects: 23
Study 1534467 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 40
Study 1534467 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 1534467 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 40
Study 1534467 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 40
Study 6536519 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin (as alphaxalone) in young group
Number of subjects: 210
Study 6536519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone in young group
Number of subjects: 210
Study 6536519 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin (as alphaxalone) in old group
Number of subjects: 210
Study 6536519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone in old group
Number of subjects: 210
Study 30393060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-screening by pregnant women
Number of subjects: 428
Study 30393060 — intervention group
Group type: COMPARATOR
Intervention: Screening by health care workers
Number of subjects: 428
Study 30393060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-screening and screening by health care workers
Number of subjects: 428
Study 29241838 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 2.2g/day
Number of subjects: 71
Study 29241838 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 71
Study 27101581 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Methotrexate (MTX), 0.4 mg/kg daily for 5 days every 14 days (25 mg maximum daily dose)
Number of subjects: 62
Study 27101581 — intervention group
Group type: COMPARATOR
Intervention: IV Actinomycin-D (Act-D), 1.25 mg/m (2 mg maximum dose) every 14 days
Number of subjects: 62
Study 27101581 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Methotrexate (MTX)
Number of subjects: 62
Study 27101581 — intervention group
Group type: COMPARATOR
Intervention: IV Actinomycin-D (Act-D)
Number of subjects: 62
Study 24747467 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game (Ace's Adventure)
Number of subjects: 348
Study 24747467 — intervention group
Group type: COMPARATOR
Intervention: Didactic session
Number of subjects: 348
Study 23302428 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with AMX + MTZ after supragingival scaling
Number of subjects: 45
Study 23302428 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with AMX + MTZ after SRP
Number of subjects: 45
Study 23302428 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 45
Study 23302428 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX + MTZ after supragingival scaling
Number of subjects: 45
Study 23302428 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX + MTZ after SRP
Number of subjects: 45
Study 20457173 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP diet (gelatin-milk protein)
Number of subjects: 65
Study 20457173 — intervention group
Group type: COMPARATOR
Intervention: SMP diet (sustained milk protein)
Number of subjects: 65
Study 20457173 — intervention group
Group type: COMPARATOR
Intervention: SSMP diet (supra-sustained milk protein)
Number of subjects: 65
Study 20457173 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP diet
Number of subjects: 65
Study 17873026 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h of continuous poikilocapnic hypoxia
Number of subjects: 12
Study 15676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (1 mg Bupi and 0.1 mg HA)
Number of subjects: 16
Study 15676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (0.5 mg Bupi and 0.1 mg HA)
Number of subjects: 16
Study 15676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (1 mg Bupi and 0 mg HA)
Number of subjects: 16
Study 15676045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D)
Number of subjects: 16
Study 15676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 16
Study 15676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 16
Study 15676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C
Number of subjects: 16
Study 12324672 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC‐HFA 500 micro g/day
Number of subjects: 20